An improved method for the determination of sulphachloropyrazine in meat and liver of broilers during and after their treatment for coccidiosis

The paper presents results of the HPLC determination of sulphachloropyrazine residues (active component of the drug „Esb3 30%”) in muscle tissue and liver of broiler chickens inoculated with laboratory-grown coccidium in the course and after treatment with this sulphonamide.Extraction of sulphachloropyrazine from samples of broiler muscle tissue and liver was carried out with a mixture of solvents dichloromethane-methanol-acetic acid (90:5:5, v/v/v), followed by extract purification by chromatographic separation on a XAD-2 column and elution of sulphachloropyrazine residues with dichloromethane. The HPLC determination of sulphachloropyrazine residues was accomplished on a Bio Sil C-8 HL 5 ?m column with a mobile phase consisting of 60% aqueous solution of acetonitrile and NH3 (pH=9.5), using a UV detector at 254 nm.The method developed allows quantitative determination of the residues of the anticoccidial agent in broiler tissue samples with a detection limit of 0.02 ?g g–1. Recovery of the method for this type of samples with a complex matrix was satisfactory, the results ranging from 79.2(0.6 to 86.7(0.2% for muscle tissue and from 81.7(0.8 to 87.3(0.7% for liver

The effect of chlorinated aromatic compounds on isolated hepatocytes

Ispitan je efekt 1,2-dihlorbenzena, 1,2,3,4- tetrahlorbenzena, 1,2,3,5- -tetrahlorbenzena, pentahlorbenzena, heksahlorbenzena i Arohlora 1254 na aktivnost enzima lipoperoksidaze i ksantinoksidaze, sadržaj citohroma P-450 i glutationa u izolovanim hepatocitima. Vijabilnost hepatocita bila je smanjena kod primene svih ispitivanih supstancija. 1,2- dihlorbenzen je smanjio sadržaj citohroma P-450 kao i aktivnost enzima, a ostali hlorbenzeni povećavali su aktivnosti enzima, ali nisu uticali na sadržaj citohroma P-450. Arohlor 1254 je povećao sadržaj citohroma P-450, a nije uticao na enzimsku aktivnost. Svi ispitivani spojevi su smanjili sadržaj glutationa.The effects of 1,2-dichlorbenzene, 1,2,3,4-tetrachlorbenzene, 1,2,3,5-tetrachlorbenzene, pentachlorbenzene, hexachlorbenzene and Arochlor 1254 on hepatocyte functions were investigated. The viability of hepatocytes as well as glutathione concentration were decreased in all treatments. 1,2- dichlorbenzene diminished the content of cytochrome P-450 and decreased lipoperoxydase and xantinoxydase activities. Under the same conditions the other compounds investigated increased lipoperoxydase and xantinoxydase activities without influencing cytochrome P-450 content. Arochlor 1254 increased the content of cytocrome P-450 in hepatocytes, but had no effect on enzyme activities

Carboxylation of phenols and asymmetric nucleophile addition across C=C bond

The regioselective carboxylation of electron-rich (hetero)aromatics employing decarboxylases in the redox-neutral (reverse) carboxylation reaction using bicarbonate or CO2(g) is currently exploited for the biocatalytic synthesis of carboxylic acids.1 Three enzyme classes exert complementary regioselectivities through diverse mechanisms: (i) Whereas the o-carboxylation of phenols (an equivalent to the Kolbe-Schmitt reaction) is mediated by Zn2+-dependent o-benzoic acid (de)carboxylases,2 (ii) the -carboxylation of hydroxystyrenes is catalysed by phenolic/ferulic acid (de)carboxylases acting via a pair of Tyr-Arg residues.3 (iii) Surpringly, these enzymes also exhibit a catalytic promiscuity for the nucleophile addition of H2O,4 NH2-OMe, cyanide and n-Pr-SH across the vinyl C=C bond via a quinone-methide intermediate, which yields the corresponding (S)-configurated adducts in up to 91% e.e.5 (iv) In search of ATP-independent regio-complementary p-benzoic acid (de)carboxylases, we discovered that 3,4-dihydroxybenzoic acid decarboxylase from Enterobacter cloacae6 (DHBDC_Ec) surprisingly depends on prenylated FMN7 as cofactor. In an attempt to propose a mechanism for the carboxylation of catechol by DHBDC_Ec, QM calculations revealed that the transient formation of a 1,3-dipolar cycloaddition product (as suggested for the decarboxylation of cinnamic acid with ferulic acid decarboxylase from S. cerevisiae8) was highly disfavored (\u3e30 kcal/M). As an alternative, we propose a mono-covalent nucleophile adduct involving a prFMN iminium electrophile (~14 kcal/M). Please click Additional Files below to see the full abstract

Evaluation of Watson-like Integrals for Hyper bcc Antiferromagnetic Lattice

Watson-like integrals for a d-dimensional bcc antiferromagnetic lattice I_d(\eta) and J_d(\eta) and another two similar integrals are evaluated in an exact way in terms of generalized hypergeometric functions. A simple formula connecting Id and Jd+1 is given along with the differential equations for I_d(\eta) and J_d(\eta). An application of I_d and J_d in the theory of the Heisenberg antiferromagnet is discussed, together with possible generalizations to non-integer values of d. Corresponding integrals for sc lattices are also briefly reviewed.Comment: 13 pages, 2 figures, Accepted for publication in Journal of Physics A: Mathematical & Theoretical 201

Impact of age at type 2 diabetes mellitus diagnosis on mortality and vascular complications: systematic review and meta-analyses

AIMS/HYPOTHESIS: Few studies examine the association between age at diagnosis and subsequent complications from type 2 diabetes. This paper aims to summarise the risk of mortality, macrovascular complications and microvascular complications associated with age at diagnosis of type 2 diabetes. METHODS: Data were sourced from MEDLINE and All EBM (Evidence Based Medicine) databases from inception to July 2018. Observational studies, investigating the effect of age at diabetes diagnosis on macrovascular and microvascular diabetes complications in adults with type 2 diabetes were selected according to pre-specified criteria. Two investigators independently extracted data and evaluated all studies. If data were not reported in a comparable format, data were obtained from authors, presented as minimally adjusted ORs (and 95% CIs) per 1 year increase in age at diabetes diagnosis, adjusted for current age for each outcome of interest. The study protocol was recorded with PROSPERO International Prospective Register of Systematic Reviews (CRD42016043593). RESULTS: Data from 26 observational studies comprising 1,325,493 individuals from 30 countries were included. Random-effects meta-analyses with inverse variance weighting were used to obtain the pooled ORs. Age at diabetes diagnosis was inversely associated with risk of all-cause mortality and macrovascular and microvascular disease (all p < 0.001). Each 1 year increase in age at diabetes diagnosis was associated with a 4%, 3% and 5% decreased risk of all-cause mortality, macrovascular disease and microvascular disease, respectively, adjusted for current age. The effects were consistent for the individual components of the composite outcomes (all p < 0.001). CONCLUSIONS/INTERPRETATION: Younger, rather than older, age at diabetes diagnosis was associated with higher risk of mortality and vascular disease. Early and sustained interventions to delay type 2 diabetes onset and improve blood glucose levels and cardiovascular risk profiles of those already diagnosed are essential to reduce morbidity and mortality. Graphical abstract

The Darkening Cloud of Diabetes: Do trends in cardiovascular risk management provide a silver lining?

OBJECTIVE—We aimed to evaluate the changes in cardiovascular-related health care utilization (drug therapies, hospitalizations) and mortality for the diabetic population during a 9-year period in Saskatchewan, Canada

CKD classification based on estimated GFR over three years and subsequent cardiac and mortality outcomes: a cohort study

<p>Abstract</p> <p>Background</p> <p>It is unknown whether defining chronic kidney disease (CKD) based on one versus two estimated glomerular filtration rate (eGFR) assessments changes the prognostic importance of reduced eGFR in a community-based population.</p> <p>Methods</p> <p>Participants in the Atherosclerosis Risk in Communities Study and the Cardiovascular Health Study were classified into 4 groups based on two eGFR assessments separated by 35.3 ± 2.5 months: sustained eGFR < 60 mL/min per 1.73 m²(1 mL/sec per 1.73 m²); eGFR increase (change from below to above 60); eGFR decline (change from above to below 60); and eGFR persistently ≥60. Outcomes assessed in stratified multivariable Cox models included cardiac events and a composite of cardiac events, stroke, and mortality.</p> <p>Results</p> <p>There were 891 (4.9%) participants with sustained eGFR < 60, 278 (1.5%) with eGFR increase, 972 (5.4%) with eGFR decline, and 15,925 (88.2%) with sustained eGFR > 60. Participants with eGFR sustained < 60 were at highest risk of cardiac and composite events [HR = 1.38 (1.15, 1.65) and 1.58 (1.41, 1.77)], respectively, followed by eGFR decline [HR = 1.20 (1.00, 1.45) and 1.32 (1.17, 1.49)]. Individuals with eGFR increase trended toward increased cardiac risk [HR = 1.25 (0.88, 1.77)] and did not significantly differ from eGFR decline for any outcome. Results were similar when estimating GFR with the CKD-EPI equation.</p> <p>Conclusion</p> <p>Individuals with persistently reduced eGFR are at highest risk of cardiovascular outcomes and mortality, while individuals with an eGFR < 60 mL/min per 1.73 m²at any time are at intermediate risk. Use of even a single measurement of eGFR to classify CKD in a community population appears to have prognostic value.</p

Study of the Emitted Dose After Two Separate Inhalations at Different Inhalation Flow Rates and Volumes and an Assessment of Aerodynamic Characteristics of Indacaterol Onbrez Breezhaler® 150 and 300 μg

Onbrez Breezhaler® is a low-resistance capsule-based device that was developed to deliver indacaterol maleate. The study was designed to investigate the effects of both maximum flow rate (MIF) and inhalation volume (Vin) on the dose emission of indacaterol 150 and 300 μg dose strengths after one and two inhalations using dose unit sampling apparatus (DUSA) as well as to study the aerodynamic characteristics of indacaterol Breezhaler® using the Andersen cascade impactor (ACI) at a different set of MIF and Vin. Indacaterol 150 and 300 μg contain equal amounts of lactose per carrier. However, 150 μg has the smallest carrier size. The particle size distribution (PSD) of indacaterol DPI formulations 150 and 300 μg showed that the density of fine particles increased with the increase of the primary pressure. For both strengths (150 μg and 300 μg), ED1 increased and ED2 decreased when the inhalation flow rate and inhaled volume increased. The reduction in ED1 and subsequent increase in ED2 was such that when the Vin is greater than 1 L, then 60 L/min could be regarded as the minimum MIF. The Breezhaler was effective in producing respirable particles with an MMAD ≤5 μm irrespective of the inhalation flow rate, but the mass fraction of particles with an aerodynamic diameter <3 μm is more pronounced between 60 and 90 L/min. The dose emission of indacaterol was comparable for both dose strengths 150 and 300 μg. These in vitro results suggest that a minimum MIF of 60 L/min is required during routine use of Onbrez Breezhaler®, and confirm the good practice to make two separate inhalations from the same dose

Altered ureteric branching morphogenesis and nephron endowment in offspring of diabetic and insulin-treated pregnancy

<div><p>There is strong evidence from human and animal models that exposure to maternal hyperglycemia during <i>in utero</i> development can detrimentally affect fetal kidney development. Notwithstanding this knowledge, the precise effects of diabetic pregnancy on the key processes of kidney development are unclear due to a paucity of studies and limitations in previously used methodologies. The purpose of the present study was to elucidate the effects of hyperglycemia on ureteric branching morphogenesis and nephrogenesis using unbiased techniques. Diabetes was induced in pregnant C57Bl/6J mice using multiple doses of streptozotocin (STZ) on embryonic days (E) 6.5-8.5. Branching morphogenesis was quantified <i>ex vivo</i> using Optical Projection Tomography, and nephrons were counted using unbiased stereology. Maternal hyperglycemia was recognised from E12.5. At E14.5, offspring of diabetic mice demonstrated fetal growth restriction and a marked deficit in ureteric tip number (control 283.7±23.3 vs. STZ 153.2±24.6, mean±SEM, <i>p</i>&lt;0.01) and ureteric tree length (control 33.1±2.6 mm vs. STZ 17.6±2.7 mm, <i>p</i> = 0.001) vs. controls. At E18.5, fetal growth restriction was still present in offspring of STZ dams and a deficit in nephron endowment was observed (control 1246.2±64.9 vs. STZ 822.4±74.0, <i>p&lt;</i>0.001). Kidney malformations in the form of duplex ureter and hydroureter were a common observation (26%) in embryos of diabetic pregnancy compared with controls (0%). Maternal insulin treatment from E13.5 normalised maternal glycaemia but did not normalise fetal weight nor prevent the nephron deficit. The detrimental effect of hyperglycemia on ureteric branching morphogenesis and, in turn, nephron endowment in the growth-restricted fetus highlights the importance of glycemic control in early gestation and during the initial stages of renal development.</p> </div

Serum kidney injury molecule 1 and β2-microglobulin perform as well as larger biomarker panels for prediction of rapid decline in renal function in type 2 diabetes

Aims/hypothesis: As part of the Surrogate Markers for Micro- and Macrovascular Hard Endpoints for Innovative Diabetes Tools (SUMMIT) programme we previously reported that large panels of biomarkers derived from three analytical platforms maximised prediction of progression of renal decline in type 2 diabetes. Here, we hypothesised that smaller (n ≤ 5), platform-specific combinations of biomarkers selected from these larger panels might achieve similar prediction performance when tested in three additional type 2 diabetes cohorts. Methods: We used 657 serum samples, held under differing storage conditions, from the Scania Diabetes Registry (SDR) and Genetics of Diabetes Audit and Research Tayside (GoDARTS), and a further 183 nested case–control sample set from the Collaborative Atorvastatin in Diabetes Study (CARDS). We analysed 42 biomarkers measured on the SDR and GoDARTS samples by a variety of methods including standard ELISA, multiplexed ELISA (Luminex) and mass spectrometry. The subset of 21 Luminex biomarkers was also measured on the CARDS samples. We used the event definition of loss of >20% of baseline eGFR during follow-up from a baseline eGFR of 30–75 ml min−1 [1.73 m]−2. A total of 403 individuals experienced an event during a median follow-up of 7 years. We used discrete-time logistic regression models with tenfold cross-validation to assess association of biomarker panels with loss of kidney function. Results: Twelve biomarkers showed significant association with eGFR decline adjusted for covariates in one or more of the sample sets when evaluated singly. Kidney injury molecule 1 (KIM-1) and β2-microglobulin (B2M) showed the most consistent effects, with standardised odds ratios for progression of at least 1.4 (p < 0.0003) in all cohorts. A combination of B2M and KIM-1 added to clinical covariates, including baseline eGFR and albuminuria, modestly improved prediction, increasing the area under the curve in the SDR, Go-DARTS and CARDS by 0.079, 0.073 and 0.239, respectively. Neither the inclusion of additional Luminex biomarkers on top of B2M and KIM-1 nor a sparse mass spectrometry panel, nor the larger multiplatform panels previously identified, consistently improved prediction further across all validation sets. Conclusions/interpretation: Serum KIM-1 and B2M independently improve prediction of renal decline from an eGFR of 30–75 ml min−1 [1.73 m]−2 in type 2 diabetes beyond clinical factors and prior eGFR and are robust to varying sample storage conditions. Larger panels of biomarkers did not improve prediction beyond these two biomarkers